Agios Pharmaceuticals
AGIO
215 hedge funds and large institutions have $2.05B invested in Agios Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 87 increasing their positions, 77 reducing their positions, and 25 closing their positions.
30% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $8.65M
16% more capital invested
Capital invested by funds: $1.76B → $2.05B (+$289M)
13% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 77
1.63% more ownership
Funds ownership: 104.89% → 106.52% (+1.6%)
3% less funds holding
Funds holding: 221 → 215 (-6)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$34.6M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$21.1M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$19.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.1M |
| 5 |
CP
Caligan Partners
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$29.4M |
| 2 |
AC
Armistice Capital
New York
|
-$26.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$15.1M |
| 4 |
BlackRock
New York
|
-$8.33M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.12M |
AGIO Hedge Fund Activity: Q2 2025 in Review
215 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2025, worth a combined $2.05B — up 16% from $1.76B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AGIO and 21 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 87 added.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $34.6M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $29.4M sold.
- 215 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2025, down from 221 in Q1 2025.
- Funds reported $2.05B of Agios Pharmaceuticals stock for Q2 2025, up 16% quarter-over-quarter.
- 21 funds opened new Agios Pharmaceuticals positions in Q2 2025 and 25 closed out, a net change of -4 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2025 was Paradigm Biocapital Advisors, an estimated $34.6M added.
- The largest Agios Pharmaceuticals seller in Q2 2025 was Polar Capital Holdings, an estimated $29.4M sold.
Based on aggregated 13F filings for Q2 2025.